Difficulty: Medium
Average Score: 68%
Practice
A 40-year old female patient is being followed up for diabetes mellitus. She is currently on Metformin 1 gram twice a day and has been tolerating it well for about six months. Her hemoglobin A1c a week ago was 8.9%. The plan is to initiate liraglutide therapy in addition to the metformin. Which of the following statements is true with regards to liraglutide.
Correct answer
C
Rationale
The correct answer is C: Nausea and/or vomiting are common side effects of therapy. Liraglutide is a GLP-1 receptor agonist commonly used to treat type 2 diabetes. The side effects of liraglutide often include gastrointestinal symptoms like nausea and vomiting. This side effect is commonly seen in patients initiating liraglutide therapy. Choices A and D are incorrect as liraglutide should not be stored in the refrigerator or freezer before use, and it is administered subcutaneously, not intramuscularly into the upper arm. Choice B is incorrect as Bydureon is a brand name for exenatide, not liraglutide.